Articles From: Exelixis Announces May 7th Webcast of First Quarter 2013 Financial Results Conference Call to EXFO and RAD Enhance Their Combined, End-to-End Network Monitoring Solution

Exelixis, Inc. (NASDAQ: EXEL) will release its first quarter 2013 financial results on Tuesday, May 7, 2013 after the markets close.

Exelixis, Inc. (NASDAQ:EXEL) today announced the presentation of updated interim data from 144 docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases treated with cabozantinib in an ongoing non-randomized expansion (NRE) cohort of its phase 2 randomized discontinuation trial.

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Exelixis, Inc. (NASDAQ:EXEL) announced today that Michael M.

Exelixis, Inc. (NASDAQ:EXEL) announced today that Michael M.

Exelixis, Inc. (NASDAQ:EXEL) today announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma (mRCC) who have experienced disease progression following treatment with at least one prior VEGFR tyrosine kinase inhibitor (TKI). The primary endpoint for the trial is progression-free survival.

Exelixis, Inc. (NASDAQ:EXEL) today announced the presentation of additional data from clinical trials of COMETRIQ™ (cabozantinib) in patients with progressive, metastatic medullary thyroid cancer (MTC). The data were presented this weekend at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO). Long-term follow-up of a phase 1 trial (Abstract #6090) shows that 30% of progressive, metastatic MTC patients treated with COMETRIQ experienced disease control (DC) and have remained progression-free for more than 2 years.

Exelixis, Inc. (NASDAQ:EXEL) and Swedish Orphan Biovitrum  (Sobi) (STO: SOBI) today announced that they have entered into a three-year agreement to support the distribution and commercialization of COMETRIQ™ (cabozantinib) for metastatic medullary thyroid cancer (MTC) in the European Union (EU) and potentially other countries.

Exelon Corporation (NYSE: EXC) announced first quarter 2013 consolidated earnings as follows: “Exelon delivered earnings at the top end of our guidance range and our nuclear fleet achieved a 96.4 percent capacity factor this quarter, highlighting our commitment to financial discipline and operational excellence,” said Christopher M.

Exelon Corporation (NYSE: EXC) announced fourth quarter and full year 2012 consolidated earnings as follows: “Exelon had another strong year of operational performance and closed on a very successful, transformational merger that gives us a presence across the value chain,” said Christopher M.

Exelon today announced that Kenneth W.

Exelon Corporation (Exelon) announced that it will redeem, on June 15, 2013 (Redemption Date), all of its outstanding Series A Junior Subordinated Debentures (NYSE: CEGPRA) (CUSIP No: 210387205)(Debentures) at a redemption price (Redemption Price) equal to 100 percent of the principal amount thereof plus accrued and unpaid interest to, but excluding, the redemption date.

Exelon today announced that its board of directors elected Anthony K.

The Board of Directors of Exelon Corporation declared a regular quarterly dividend of $0.31 per share on Exelon’s common stock.

Thousands of employees from across the Exelon family of companies are observing National Volunteer Week (April 21-27) by participating in more than 150 volunteer service projects in the communities Exelon serves.

Exelon Generation Company, LLC (Generation) announced today that it will extend the deadline with respect to its exchange offer to exchange (i) $523,303,000 of its 4.25% Senior Notes due 2022 (new 2022 notes), which have been registered under the Securities Act of 1933 (Securities Act), for $523,303,000 of its currently outstanding 4.25% Senior Notes due 2022, which were issued in a private placement in compliance with Rule 144A and Regulation S under the Securities Act (outstanding 2022 notes); and (ii) $788,203,000 of its 5.60% Senior Notes due 2042, which have been registered under the Securities Act (new 2042 notes, and collectively with the new 2022 notes, the new notes) for $788,203,000 of its currently outstanding 5.60% Senior Notes due 2042, which were issued in a private placement in compliance with Rule 144A and Regulation S under the Securities Act (outstanding 2042 notes, and

For most people, one full-time job is enough, but a leading national energy company is honoring a select group of its employees for their dedication to their second jobs — as volunteers in their communities.

Exelon Corporation (NYSE: EXC) was awarded the International Business Leadership Award Saturday at Equality Forum’s 2013 International Equality Dinner, part of an annual lesbian, gay, bisexual and transgender (LGBT) civil rights summit held May 2-5 in Philadelphia.

In an effort to promote diversity and inclusion at the firms that support its finance organization, Exelon has recognized 11 banks, insurance companies and professional services organizations for demonstrating an exceptional commitment to these values in 2012.

Exelon Corp.

Exelon Corp.

PECO Energy Company (PECO) today announced that it issued a notice of redemption for all of the following series of preferred stock: The redemption date for each of the above series of preferred stock will be May 1, 2013.

Directors of PECO Energy Company have declared dividends on all series of preferred stock, payable May 1, 2013, to shareholders of record at the close of business on March 28, 2013, as follows: Exelon Corporation (NYSE: EXC) is the nation’s leading competitive energy provider, with 2012 revenues of approximately $23.5 billion.

http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1003757&ProfileId=051205&sourceType=1 NICOSIA, CYPRUS --

http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0859323001&sourceType=1 http://www.ccnmatthews.com/logos/20090201-exlo.JPG VANCOUVER, BRITISH COLUMBIA --

http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0877715001&sourceType=1 http://www.ccnmatthews.com/logos/20090201-exlo.JPG VANCOUVER, BRITISH COLUMBIA --

http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0875859001&sourceType=1 http://www.ccnmatthews.com/logos/20090201-exlo.JPG VANCOUVER, BRITISH COLUMBIA --

EXFO Adds Bidirectional Testing to Its Innovative iOLM Fiber Characterization Technology Canada NewsWire This patent-pending testing functionality simplifies the complex, time-consuming bidirectional measurements required for a true splice-loss assessment.

EXFO and RAD Enhance Their Combined, End-to-End Network Monitoring Solution Canada NewsWire In addition to RAD's ETX EtherAccess Ethernet demarcation device, EXFO's Brix Service Assurance solution for network provisioning, troubleshooting and maintenance now supports RAD's new MiNID Service Assurance SFP.